BioSpace News Archive

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”),and AVEO Oncology (NASDAQ: AVEO) (“AVEO”), today announced that they have entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, also known as HER3.

Amyris, Inc. announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2021, on the morning of Tuesday, March 1, 2022, prior to the opening of the financial markets.

Applied DNA Sciences, Inc. announced that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 1,496,400 shares of common stock at a price of $2.80 per share, in a registered direct offering, resulting in total gross proceeds of approximately $4.2 million, before deducting the placement agent’s fees and other estimated offering expenses.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 13 company-sponsored data presentations from its multiple sclerosis (MS) research program will be presented at the 2022 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum.

Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close.

Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), today announced a publication in Cancer Research by scientists from the University of Edinburgh titled Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors, highlighting NXP900’s robust activity in preclinical models of Triple Negative Breast Cancer (“TNBC”) with Integrin-Linked Kinase (“ILK”) loss.

NeuroSense Therapeutics Ltd. today announced that it will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 25th at 8:30AM Eastern.

Advanced analytical tools such as SWOT analysis and Porter’s Five Forces analysis along with details diagrams, graphs, and figures have been applied in this study.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.